Latest Artrya (ASX:AYA) News

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Artrya Limited has responded to an ASX price query following a notable surge in its share price, confirming no undisclosed information and adherence to continuous disclosure rules.